NO944182L - Kompleksdannende midler og målsökende immunreagenser - Google Patents

Kompleksdannende midler og målsökende immunreagenser

Info

Publication number
NO944182L
NO944182L NO944182A NO944182A NO944182L NO 944182 L NO944182 L NO 944182L NO 944182 A NO944182 A NO 944182A NO 944182 A NO944182 A NO 944182A NO 944182 L NO944182 L NO 944182L
Authority
NO
Norway
Prior art keywords
reactive group
protein reactive
alkoxy
alkyl
represents hydrogen
Prior art date
Application number
NO944182A
Other languages
English (en)
Other versions
NO944182D0 (no
Inventor
John L Toner
David A Hilborn
Bruce J Murray
Timothy Z Houssain
Robert A Snow
Ashis Kumar Saha
Richard Philion
Clyde W Shearman
Chandra Shah
Original Assignee
Sterling Winthrop Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sterling Winthrop Inc filed Critical Sterling Winthrop Inc
Publication of NO944182D0 publication Critical patent/NO944182D0/no
Publication of NO944182L publication Critical patent/NO944182L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6887—Antibody-chelate conjugates using chelates for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Et målsøkende radioaktivt immunreagens omfattende et metall radlonuklldlon, et kompleksdannende middel og en Immunreaktlv gruppe kovalent bundet til nevnte kompleksdannende middel, l det det kompleksdannende mldle~r har strukturen (AI), hvor R betyr hydrogen, alkyl, alkoksy, alkyltlo, alkylamlno, alkylformamido, aryl, aryloksy, heterocyklyl eller en protein reaktlv gruppe; R1 betyr hydrogen, alkyl, alkoksy, alkyltlo, alkylamlno, alkylformamido, aryl, aryloksy, hetero- cyklyl eller en protelnreaktlv gruppe; R2 betyr hydroksy, karboksy, hydroksyalkyl, tloalkyl, formyl, karbonyllmlnodleddlksyre, metylenlmlnodieddlksyre, metylentioetyleniminodleddlksyre, karboksyalkyltlo- alkyl, hydrazlnylldendleddlksyre eller et salt av silke syrer, eller to R^ grupper, som sammen representerer atomene som er nødvendige for å fullføre en makro- cykllsk rlngstruktur Inneholdende minst et heteroatom koordlnerlngssete og minst en, fortrinnsvis to alkylengrupper som danner en del av rlngstrukturen; R3 betyr hydrogen, alkyl, alkoksy, alkyltio, alkylamlno, alkylformamido, aryl, aryloksy, heterocyklyl eller en protein reaktlv gruppe; R4 betyr hydrogen eller en protein reaktlv gruppe; n betyr O til 4; o betyr O eller 1; n betyr O eller 1; forutsatt at minst en av n og m er O og minst en av R» R1, R3 og R4 er en protelnreaktiv gruppe. Videre er nye terpyrldlner, quatærpyrldiner, qulnqepyrldiner, sexlpyridiner og fenantroliner med strukturen (AI) beskrevet. Foretrukne terpyrldiner har strukturen AI ovenfor, hvor n - l, o - l, m - O og R er en proteinreaktlv gruppe eller en fenyl substituert med en proteinreaktiv gruppe. Eventuelt kan fenyl også Inneholde en eller flere substituenter valgt fra alkyl eller alkoksy. Foretrukne fenantroliner har strukturen (AI) ovenfor hvor n - O, o - l, m - l og minst en R4 er en proteinreaktiv gruppe. De målsøkende radioaktive Immunreagensene er spesielt nyttige Innen terapeutiske og diagnostiske bllled- dannende sammensetninger og metoder.
NO944182A 1992-05-07 1994-11-02 Kompleksdannende midler og målsökende immunreagenser NO944182L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1992/003858 WO1993021957A1 (en) 1992-05-07 1992-05-07 Complexing agents and targeting immunoreagents

Publications (2)

Publication Number Publication Date
NO944182D0 NO944182D0 (no) 1994-11-02
NO944182L true NO944182L (no) 1994-12-21

Family

ID=22231055

Family Applications (1)

Application Number Title Priority Date Filing Date
NO944182A NO944182L (no) 1992-05-07 1994-11-02 Kompleksdannende midler og målsökende immunreagenser

Country Status (12)

Country Link
EP (1) EP0639083B1 (no)
JP (1) JP3358141B2 (no)
KR (1) KR950701229A (no)
AT (1) ATE203168T1 (no)
AU (1) AU672951B2 (no)
BR (1) BR9207126A (no)
CA (1) CA2135059A1 (no)
DE (1) DE69231952T2 (no)
FI (1) FI945194A (no)
NO (1) NO944182L (no)
RU (1) RU2122431C1 (no)
WO (1) WO1993021957A1 (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5480970A (en) * 1993-12-22 1996-01-02 Resolution Pharmaceuticals Metal chelators
US5569745A (en) * 1994-02-25 1996-10-29 Resolution Pharmaceuticals Inc. Peptide-Chelator conjugates
DE19505960A1 (de) * 1995-02-21 1996-08-22 Deutsches Krebsforsch Konjugat zur individuellen Dosierung von Arzneimitteln
US6004529A (en) * 1997-04-11 1999-12-21 Nycomed Imaging As Chelating agents
AU3282300A (en) * 1999-02-24 2000-09-14 Mallinckrodt, Inc. Molecules for the treatment and diagnosis of tumors
US6844425B1 (en) 1999-02-24 2005-01-18 Mallinckrodt Inc. Combination of intercalating organometallic complexes and tumor seeking biomolecules for DNA cleavage and radiotherapy
AU2003211865A1 (en) * 2002-03-08 2003-09-22 Mitsubishi Rayon Co., Ltd. Novel fluorescent label compounds
KR101528013B1 (ko) * 2009-08-31 2015-06-16 로슈 글리카트 아게 친화성-성숙된 인간화된 항-ｃｅａ 단일클론 항체
RU2454931C1 (ru) * 2011-03-02 2012-07-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт онкологии имени Н.Н. Петрова" Министерства здравоохранения и социального развития Российской Федерации Способ диагностики распространенности опухолевого процесса у больных немелкоклеточным раком легкого

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837169A (en) * 1981-07-01 1989-06-06 Eastman Kodak Company Polypyridine Fluorescent labels for immunoassay
EP0171978B1 (en) * 1984-08-13 1990-11-07 HSC Research Development Corporation 1,10-phenanthroline-2,9-dicarboxylic acid-derivatives and their use in fluorescent immunoassay
DK365785A (da) * 1984-09-17 1986-03-18 Hoffmann La Roche Metalcomplexer
AU8152887A (en) * 1986-10-17 1988-05-06 Cytogen Corporation Method for preparation of protein-chelator-metal ion compositions suitable for injection
SE8802575D0 (sv) * 1988-07-08 1988-07-08 Wallac Oy Terpyridine derivatives
GB9001245D0 (en) * 1990-01-19 1990-03-21 Salutar Inc Compounds
US5367080A (en) * 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
CA2150477A1 (en) * 1992-11-30 1994-06-09 Robert Allen Snow Sequential targeting of tumor sites with oligonucleotide conjugates of antibody and complementary oligonucleotide conjugates of chelated radionuclide
EP0691981A1 (en) * 1993-03-10 1996-01-17 The Wellcome Foundation Limited Tumor targeting with l-enantiomeric oligonucleotide conjugates of immunoreagents and of chelated radionuclides

Also Published As

Publication number Publication date
JP3358141B2 (ja) 2002-12-16
BR9207126A (pt) 1995-08-29
CA2135059A1 (en) 1993-11-11
JPH07506667A (ja) 1995-07-20
AU672951B2 (en) 1996-10-24
ATE203168T1 (de) 2001-08-15
FI945194A (fi) 1995-01-04
RU2122431C1 (ru) 1998-11-27
DE69231952T2 (de) 2002-04-04
KR950701229A (ko) 1995-03-23
WO1993021957A1 (en) 1993-11-11
EP0639083A1 (en) 1995-02-22
DE69231952D1 (de) 2001-08-23
AU2316192A (en) 1993-11-29
FI945194A0 (fi) 1994-11-04
EP0639083B1 (en) 2001-07-18
NO944182D0 (no) 1994-11-02
RU94046010A (ru) 1996-10-20

Similar Documents

Publication Publication Date Title
WO1992008494A3 (en) Targeting radioactive immunoreagents
DK326785A (da) Terapeutisk middel til paavisning og/eller behandling af tumorer og fremgangsmaade til fremstilling af et saadant middel
NO944182D0 (no) Kompleksdannende midler og målsökende immunreagenser
MY107655A (en) Derivatives of benzofuran,benzothiophene,indole and indolizine,process for their preparation as well as the compositions containing them
PT883627E (pt) Marcacao de radionuclidos de vitamina b12 e de coenzimas
HU9402726D0 (en) Method of tumor treatment
IL90651A (en) Stable, cold water- dispersible preparations of fat-soluble substances
CA2109208A1 (en) Radiolabeled metal-binding protein for the treatment of arthritis
DE3267375D1 (en) M-4 and iso m-4 derivatives, their preparation and compositions containing them
FR2613365B1 (fr) Nouveaux derives de l'amino tetrahydro-5, 6, 7, 8 naphto (2, 3b) furanne, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
FI95907B (fi) Proteiinin merkkaus
IL95327A0 (en) Method and composition for the treatment of cardiac and of vascular hypertrophy and hyperplasia
IL82629A0 (en) Substituted 6-hydroxymethyl-carbapenem antibiotics,the preparation thereof and pharmaceutical compositions containing them
RU93033092A (ru) Комплексообразующие вещества и целенаправленные радиоактивные иммунореагенты, композиции на их основе и способы лечения и диагностического исследования с применением указанных композиций
ATE55389T1 (de) 99mtc(iii)-agenzien zur myokardialen darstellung, in vivo nichtreduzierbar.
IL83088A (en) Substituted 3-isoquinolinols,their preparation and pharmaceutical compositions containing them
DE3570677D1 (en) Acino-foetal differentiation proteins associated with cancer of the pancreas, antiserum and monoclonal antibodies against these proteins and processes for their preparation
DK0700930T3 (da) Tumoraffinitetspeptid og radioaktivt diagnosticeringsmiddel og radioaktivt behandlingsmiddel indeholdende peptidet
DK164362C (da) Triazolderivater og farmaceutiske praeparater indeholdende disse
ES8602676A1 (es) Un procedimiento para la preparacion de nuevos derivados de pirrolo-(2,1-a)isoquilonina.
CA2031528A1 (en) Radionuclide metal chelates for the radiolabeling of proteins

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application